Bio-Rad Laboratories, Inc.
BIO
$305.56
-$0.99-0.32%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -675.90M | 319.20M | -2.16B | -1.84B | -778.67M |
| Total Depreciation and Amortization | 162.10M | 156.80M | 152.60M | 151.60M | 149.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.20B | -67.20M | 3.16B | 2.77B | 1.45B |
| Change in Net Operating Assets | -197.70M | 125.40M | -631.20M | -620.80M | -413.00M |
| Cash from Operations | 491.50M | 534.20M | 515.30M | 455.20M | 412.00M |
| Capital Expenditure | -154.71M | -163.21M | -159.81M | -165.61M | -164.97M |
| Sale of Property, Plant, and Equipment | 51.00K | 51.00K | 51.00K | 51.00K | 196.00K |
| Cash Acquisitions | -218.50M | -216.70M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 2.50M |
| Other Investing Activities | 187.12M | 181.12M | 45.52M | 5.32M | 104.76M |
| Cash from Investing | -186.04M | -198.74M | -114.24M | -160.24M | -57.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -341.00K | -441.00K | -341.00K | -441.00K | -551.00K |
| Issuance of Common Stock | 15.81M | 17.51M | 18.01M | 19.21M | 19.63M |
| Repurchase of Common Stock | -298.23M | -343.33M | -304.23M | -207.03M | -411.65M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -29.98M | -29.98M | -29.98M | -30.58M | -600.00K |
| Cash from Financing | -312.75M | -356.25M | -316.55M | -218.85M | -393.17M |
| Foreign Exchange rate Adjustments | -6.68M | -15.18M | 4.82M | 9.32M | -7.39M |
| Miscellaneous Cash Flow Adjustments | -48.00K | -48.00K | -48.00K | -48.00K | 4.00K |
| Net Change in Cash | -14.02M | -36.02M | 89.28M | 85.38M | -46.07M |